HORSHAM, PA — Myonex has announced the successful completion of its acquisition of Creapharm’s pharmaceutical services business. This acquisition is set to enhance Myonex’s position in the market by integrating Creapharm’s expertise in clinical packaging, distribution, commercial packaging operations, and bioservices. The newly acquired entity will operate under the banner of Creapharm, now a subsidiary of Myonex.
James Lovett, CEO of Myonex, expressed enthusiasm about the acquisition, emphasizing its significance in expanding the company’s service portfolio and its ability to adapt to the evolving needs of its clients. “Together, we are poised to meet the dynamic needs of our clients with agility, flexibility, and reliability,” Lovett remarked.
Further solidifying its leadership structure, Myonex welcomed Eric Placet, the founding visionary behind CREAPHARM, to its Board of Directors. Placet’s reinvestment in the company underscores a shared dedication to excellence and innovation within the merged entity. Additionally, the appointment of Carla Da Costa as Chief Operating Officer is poised to inject fresh momentum into Myonex’s operational strategy as it eyes further growth and enhanced client service.
This acquisition not only marks a milestone for Myonex in terms of service expansion but also signifies a significant step in catering to advanced therapies, a rapidly growing sector within the pharmaceutical industry. The inclusion of Creapharm’s capabilities is expected to provide an integrated solution for clients across clinical and commercial stages, particularly for those managing advanced therapies which demand specialized packaging and distribution services.
The transaction was supported by a team of legal and financial advisors, including McDermott, Will & Emery, Troutman Pepper, and Crosstree Capital Partners for Myonex, and ARST Avocats, Nomodos, Nelson Mullins, and Rothschild&Co for Creapharm, illustrating the complex and collaborative nature of such international business deals.
With this acquisition, Myonex and Creapharm are setting a robust framework for future growth, leveraging their combined strengths to offer comprehensive services to the pharmaceutical and biotech industries. This strategic consolidation is anticipated to enhance the competitive advantage of both entities, fostering innovation and excellence in a highly regulated and competitive market.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.